Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 3/20 | 0.61 |
| ▸ | HTR5A | P47898 | 2/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.61 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.61 |
| ▸ | HTR3B | O95264 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | HTR1A | P08908 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | NCF1 | P14598 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.61 |
| ▸ | HTR1D | P28221 | 1/20 | 0.61 |
| ▸ | HTR1B | P28222 | 1/20 | 0.61 |
| ▸ | HTR2A | P28223 | 1/20 | 0.61 |
| ▸ | HTR7 | P34969 | 1/20 | 0.61 |
| ▸ | MTOR | P42345 | 1/20 | 0.61 |
| ▸ | HTR3A | P46098 | 1/20 | 0.61 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.61 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.61 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4244450 | 1.00 | HTR6 (0.61) | HTR6HTR5AHSD17B10HTR3EHTR3B | |
| SCHEMBL4247868 | 1.00 | HTR6 (0.61) | HTR6HTR5AHSD17B10HTR3EHTR3B | |
| SCHEMBL6552879 | 0.83 | HTR1A (0.42) | HTR6HTR5AHSD17B10HTR3EHTR3B | |
| SCHEMBL6552932 | 0.83 | HTR5A (0.46) | HTR6HTR5AHSD17B10HTR3EHTR3B | |
| SCHEMBL14146963 | 0.83 | PRKCQ (0.59) | HTR6HTR5AHSD17B10HTR3EHTR3B | |
| SCHEMBL6552931 | 0.83 | HTR5A (0.46) | HTR6HTR5AHSD17B10HTR3EHTR3B | |
| SCHEMBL6553062 | 0.83 | HTR5A (0.46) | HTR6HTR5AHSD17B10HTR3EHTR3B | |
| SCHEMBL9063997 | 0.83 | HTR5A (0.67) | HTR6HTR5AHSD17B10HTR3EHTR3B | |
| SCHEMBL6552882 | 0.83 | HTR1A (0.42) | HTR6HTR5AHSD17B10HTR3EHTR3B | |
| SCHEMBL5090632 | 0.83 | HTR1A (0.42) | HTR6HTR5AHSD17B10HTR3EHTR3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090036455-A1 | ARYLPIPERAZINE DERIVATIVE AND USE THEREOF AS 5-HT1A RECEPTOR LIGANDS | CEPA SCHWARZ PHARMA, S.L. (ES) | 2009-02-05 | — | — | US | disclosed |
| EP-1674103-A1 | Arylpiperazine derivatives and use thereof as 5-HT1A receptor ligands | Cepa Schwarz Pharma s.l. (ES) | 2006-06-28 | — | — | EP | disclosed |
| US-20040122001-A1 | Pharmaceutical compounds | ELI LILLY AND COMPANY | 2004-06-24 | — | — | US | disclosed |
| EP-1345930-A2 | PHARMACEUTICAL COMPOUNDS | ELI LILLY AND COMPANY (US) | 2003-09-24 | — | — | EP | disclosed |
| WO-2002050067-A2 | PHARMACEUTICAL HETEROCYCLIC COMPOUNDS | ELI LILLY AND COMPANY (US) | 2002-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036455-A1 | ARYLPIPERAZINE DERIVATIVE AND USE THEREOF AS 5-HT1A RECEPTOR LIGANDS | HTR1A, HTR5A, HTR2C | HTR6 12/4885HTR5A 2/4885HSD17B10 3819/4885 |
| US-20040122001-A1 | Pharmaceutical compounds | CYP2D6, LPXN, CYP1B1 | HTR6 863/4885HTR5A 724/4885HSD17B10 1206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.